You said "WE" so assumed you where including yourself in the statement.
Look, a few posters have brought the worse out in me. I am not someone who normally will go back and forth with someone over and over again. But when I see my username being hosed day after day it gets real fuxxing old. You don't think I know the company has shot themselves in the foot at just about every turn? It doesn't take away the fact etrm was granted FDA approval which some might say was miraculous in itself, but they did! So reading through many articles, listening to the real "qualified individuals" I made my decision to stick it out with the hopes provider coverage wasn't to far behind, it is starting. The device works, now whether etrm makes it a successful device for the BILLION dollar market they are in is still anyone's guess.
Good luck man, we all need a little of it with our investments, especially when playing with "spec" plays.
Sorry, it was Netflix big difference
"I guess I am hoping that one day we would all collectively be brave enough to stop the madness of thinking ETRM is going to become the next NFLX"
You say we, like you are speaking for us which would have included myself. Enetromedics the next Netflix, never in my wildest dreams! If you would have said some company worth a couple hundred Million bucks I would agree.
Jomar, you are talking with someone who once thought etrm was going to be the next Tesla. My impression of deux is someone who is a sore loser who blames everyone but himself. Duex will soon be hating on "oozz and all his alias" for dragging him into cldx. Hey, speaking of, anyone seen ooz? You know "Mr. Qualified" the one and only great one!
OREX.ACHN,CDLX not my picks, just saying!
Moral of the story," NO ONE" is ever right.
Forever long ETRM!!
Sander Gerber just filed a "Statement of acquisition of beneficial ownership", which is also known as a 13G. In the filing, it appears as though Sander Gerber claims to own 11,167,324 shares. This represents 9.50% of EnteroMedics Inc..
Dem if you know, could these firm be buying from the shelf. If I remember correctly since it was approved the company doesn't need to file anything if they chose. Is this correct or am I wrong?
Sounds like it. As you know they have been talking about the technology being used to treat obesity for years. It is now available with words like "revolutionary" being tossed around. I'm tired of hearing vbloc doesn't work from the peanut gallery! No sane reputable doctor is going to recommend, promote, or implant a device if it doesn't work! And no employer is going to offer it to their 8000 employees and their spouses if it doesn't work! It has been a long slog and will probably continue o be so. But for patient ones it may just pay off!
I don't know what will happen tomorrow. What I do know is 10 years ago Medtronic was interested in pretty much the same technology. Now whether or not they are still interested is anybody's guess. But if Medtronic was willing to fork out $100's of millions for a technology before it was approved for use, they must be intrigued that ETRM got the green light when they failed. So again, do you have a better model for me to go by?
Transneuronix device without FDA approval: $275M
EnteroMedics device with FDA approval $8M
You read it, responded, so I deleted it. You tell me to worry about me, well its hard to do when I see my screen name being hosed day after day. I am invested in the company for the long haul, you are not. You have done nothing but bash the company throwing salt on posters open wounds for a year now.
And how the hell do I bring harm to people? Again, I generally post facts with links sometimes posting an opinion. So which is better, "we are going to tha moon, company worth $10B" or just simple links related to EnteroMedics?
Sentiment: Strong Buy
Ballpark $300M but what I didn't mention is Medtronic bought the company before an FDA decision. Guess what, it got whacked and never was approved for use.
Here is why i refuse to sell.
MINNEAPOLIS – June 29, 2005 – Medtronic, Inc. (NYSE: MDT), today announced that it has agreed to acquire Transneuronix, Inc., a privately held medical device company focused on the treatment of obesity by stimulation of the stomach with an implantable pacemaker-like device. The product delivers electrical pulses to the stomach. The acquisition has been approved by Transneuronix stockholders and the parties have received early termination of the waiting period under the Hart-Scott-Rodino Act. The transaction is expected to close within the week.
The acquisition follows Medtronic’s recent announcement regarding the formation of a new business unit, Medtronic Obesity Management. “The acquisition of Transneuronix plays a key part in our strategy to deliver therapeutic solutions for the worldwide challenges of obesity,” said Bill Hawkins, Medtronic president and chief operating officer. “Because obesity is linked to so many associated health problems, there is a great sense of urgency to find successful long-term treatment options for these patients.”
“Medtronic has been invested in Transneuronix, and we know the technology very well,” said Gary Lubben, vice president and general manager of Medtronic Obesity Management. “Through
Transneuronix’s clinical trial and European market experience, we are confident that we can grow this business and help patients and physicians address a very troubling disease.” Medtronic has been a supplier of the company’s implantable stimulation devices and programmers.
Under the agreement, Medtronic will acquire Transneuronix for an initial payment of approximately $260 million and will make additional payments to Transneuronix shareholders if significant revenue objectives are achieved.
Transneuronix has been conducting research using gastric electrical stimulation for the treatment of obesity for more than eight years in the United States and Europe. Since the first implant in 1995, more than 700 patients have been implanted with Transcend®, the company’s Implantable Gastric Stimulator (IGS®). More than 300 patients have been enrolled in Transneuronix-sponsored trials that have demonstrated meaningful reductions in excess weight with a good safety profile. Most current therapies designed to treat obesity involve highly invasive surgical procedures with significant early and late complications. The Transcend system has been commercially available in Europe for more than three years, and Transneuronix recently received regulatory approval to begin marketing the Transcend system in Canada.
In the United States, Transneuronix has completed enrollment in its U.S. pivotal trial. The U.S. trial is a multi-center, blinded, randomized control study designed to demonstrate weight loss in comparison to a control group.
“Transneuronix has made great strides in the development of gastric electrical stimulation over the last five years through product enhancements, clinical trials and advances in patient identification and selection,” said Dr. Louis J. Aronne, clinical professor of medicine at Weill Cornell Medical College, adjunct clinical associate professor of medicine at Columbia University, director of the Comprehensive Weight Control Program at New York-Presbyterian Hospital, and president of the North American Association for the Study of Obesity.
“We look forward to the clinical results of the U.S. trial this fall and hope this therapy becomes available to patients in the United States in the near future,” added Dr. Aronne. New York-Presbyterian Hospital/Columbia University Medical Center is one of eight sites in the United States participating in the trial.
Obese people have an increased risk of developing other serious medical problems such as diabetes, heart disease, high blood pressure, stroke and cancer. The National Institute of Diabetes & Digestive & Kidney Diseases estimates that patients with a high Body Mass Index (BMI) cost the U.S. healthcare system more than $60 billion a year in direct medical costs.
Medtronic Initiates Feasibility Trial of Transneuronix Technology in Diabetes Patients
Medtronic also announced its initiation of the ASSIST (Appetite Suppression Induced by Stimulation Trial) feasibility trial to test the safety and efficacy of gastric electrical stimulation (GES) for the treatment of obesity in patients with type 2 diabetes. The first implant occurred June 7, 2005, at Scripps Memorial Hospital La Jolla, in San Diego. Dr. Mark Sherman performed the implant of the gastric stimulator and two stimulation leads. The leads, or wires, are implanted into the wall of the stomach via laparoscopy.
The ASSIST trial is designed to determine if type 2 diabetes patients with concomitant obesity who receive gastric electrical stimulation have a minimum mean excess weight loss greater than a control group. The trial will evaluate excess weight loss and glycemic control. The feasibility trial will take place in a small number of select centers in the United States.
“Gastric electrical stimulation could be a solution that provides treatment options for weight loss and subsequent reduction of type 2 diabetes mellitus,” said Dr. Daniel Einhorn, an endocrinologist and principal investigator at Scripps La Jolla. “This study brings a multi-disciplined approach to obesity and diabetes management, and provides the opportunity to improve management with other therapeutic and surgical options for obesity.”
Greeting you as you walk into work you see a new sign of a man who lost a WHOPPING 53 pounds in just 3 short months. With much amazement not only do you see the dramatic change in the guy in the sign, you find out he had the procedure where you work who is now offering the procedure to their 8000 employees and their spouses. Who would of ever thought you could possibly go to work, have the vbloc procedure performed, and quite very possibly walk down the hall or go up/down a few floors right back to work!
Celebrate by eating a twinkee!!
If this doesn't move the needle on speculation alone nothing will. The coverage is for not only 8000 employees but their spouses as well. HUGE!!
A recent patient has experienced a 52 lb weight loss in three months and is already off several medications, resulting in significant savings to his insurance company. Reducing time lost from work and medical expenses is, in fact, a win for everyone."